Marc Cantillon

2.7k total citations
53 papers, 1.5k citations indexed

About

Marc Cantillon is a scholar working on Psychiatry and Mental health, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Marc Cantillon has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 11 papers in Pharmacology and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Marc Cantillon's work include Schizophrenia research and treatment (11 papers), Dementia and Cognitive Impairment Research (10 papers) and Treatment of Major Depression (9 papers). Marc Cantillon is often cited by papers focused on Schizophrenia research and treatment (11 papers), Dementia and Cognitive Impairment Research (10 papers) and Treatment of Major Depression (9 papers). Marc Cantillon collaborates with scholars based in United States, Canada and Australia. Marc Cantillon's co-authors include Susan G. Kornstein, Michael E. Thase, Richard Entsuah, Susan Huyck, Emmanuelle Pourcher, Kenneth Wolski, Robert A. Hauser, David Hackett, Jonathan Davidson and V. Haudiquet and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and The Lancet Neurology.

In The Last Decade

Marc Cantillon

53 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marc Cantillon United States	20	558	340	221	190	182	53	1.5k
Björn Mårtensson Sweden	24	488 0.9×	440 1.3×	159 0.7×	388 2.0×	147 0.8×	56	2.1k
Panagiotis Ferentinos Greece	22	519 0.9×	206 0.6×	203 0.9×	114 0.6×	352 1.9×	116	1.5k
Riccardo Torta Italy	24	559 1.0×	270 0.8×	127 0.6×	115 0.6×	88 0.5×	74	1.7k
Muhammad Ishrat Husain Canada	24	509 0.9×	280 0.8×	152 0.7×	147 0.8×	184 1.0×	146	2.0k
Richard Musil Germany	25	864 1.5×	302 0.9×	178 0.8×	193 1.0×	104 0.6×	100	2.0k
Stephan Köhler Germany	19	307 0.6×	271 0.8×	259 1.2×	130 0.7×	181 1.0×	71	1.4k
Rebecca Strawbridge United Kingdom	21	652 1.2×	480 1.4×	319 1.4×	87 0.5×	170 0.9×	80	2.5k
Jun Ishigooka Japan	24	757 1.4×	291 0.9×	215 1.0×	196 1.0×	116 0.6×	123	1.6k
Akira Kugaya Japan	26	425 0.8×	260 0.8×	133 0.6×	430 2.3×	70 0.4×	45	2.6k
Tae‐Youn Jun South Korea	29	767 1.4×	528 1.6×	395 1.8×	250 1.3×	118 0.6×	125	2.4k

Countries citing papers authored by Marc Cantillon

Since Specialization

Citations

This map shows the geographic impact of Marc Cantillon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Cantillon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Cantillon more than expected).

Fields of papers citing papers by Marc Cantillon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Cantillon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Cantillon. The network helps show where Marc Cantillon may publish in the future.

Co-authorship network of co-authors of Marc Cantillon

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Cantillon. A scholar is included among the top collaborators of Marc Cantillon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Cantillon. Marc Cantillon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cantillon, Marc, Nancy C. Andreasen, & Niels D. Prins. (2024). Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 11(1). 65–70. 3 indexed citations

Henderson, Samuel T., et al.. (2024). Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study. Journal of the Neurological Sciences. 464. 123147–123147. 1 indexed citations

Mortby, Moyra E., Lawrence Adler, Luis Agüera-Ortíz, et al.. (2021). Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. American Journal of Geriatric Psychiatry. 30(2). 119–147. 43 indexed citations

Alva, Gustavo, Jason Aldred, Bruce Coate, et al.. (2020). An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression. Journal of Parkinson s Disease. 10(4). 1751–1761. 13 indexed citations

Rajagopal, Lakshmi, et al.. (2017). RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behavioural Brain Research. 332. 180–199. 24 indexed citations

Hawkinson, Jon E., et al.. (2017). RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats. European Journal of Pharmacology. 810. 92–99. 21 indexed citations

Ismail, Zahinoor, Jennifer R. Gatchel, Daniel R. Bateman, et al.. (2017). Affective and emotional dysregulation as pre-dementia risk markers: exploring the mild behavioral impairment symptoms of depression, anxiety, irritability, and euphoria. International Psychogeriatrics. 30(2). 185–196. 146 indexed citations

Hawkinson, Jon E., et al.. (2017). RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia–induced pulmonary arterial hypertension in rats. European Journal of Pharmacology. 810. 83–91. 19 indexed citations

Cantillon, Marc, et al.. (2017). Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder. Schizophrenia Research. 189. 126–133. 39 indexed citations

10.

Gan, Tong J., Jiezhun Gu, Neil Singla, et al.. (2011). Rolapitant for the Prevention of Postoperative Nausea and Vomiting. Anesthesia & Analgesia. 112(4). 804–812. 38 indexed citations

11.

Frank, Lori, William R. Lenderking, Kellee Howard, & Marc Cantillon. (2011). Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease. Alzheimer s Research & Therapy. 3(6). 35–35. 40 indexed citations

12.

Hauser, Robert A., Marc Cantillon, Emmanuelle Pourcher, et al.. (2011). Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. The Lancet Neurology. 10(3). 221–229. 153 indexed citations

13.

Files, James G., et al.. (2007). Measured Neutralizing Titers of IFN- β Neutralizing Antibodies (NAbs) Can Depend on the Preparations of IFN- β Used in the Assay. Journal of Interferon & Cytokine Research. 27(8). 637–642. 15 indexed citations

14.

Thase, Michael E., Richard Entsuah, Marc Cantillon, & Susan G. Kornstein. (2005). Relative Antidepressant Efficacy of Venlafaxine and SSRIs: Sex-Age Interactions. Journal of Women s Health. 14(7). 609–616. 162 indexed citations

15.

Cantillon, Marc, et al.. (2005). Preliminary safety, tolerability and efficacy of ALGRX 4975 in Osteoarthritis (OA) of the knee. Journal of Pain. 6(3). S39–S39. 6 indexed citations

16.

Davidson, Jonathan, et al.. (2002). Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depression and Anxiety. 16(1). 4–13. 110 indexed citations

17.

Harwood, Dylan G., Warren Barker, Marc Cantillon, et al.. (1998). Depressive Symptomatology in First-Degree Family Caregivers of Alzheimer Disease Patients: A Cross-Ethnic Comparison. Alzheimer Disease & Associated Disorders. 12(4). 340–346. 96 indexed citations

18.

Cantillon, Marc, Dylan G. Harwood, Warren Barker, et al.. (1997). No association between apolipoprotein E genotype and late-onset depression in Alzheimer's disease. Biological Psychiatry. 41(2). 246–248. 35 indexed citations

19.

Hellerstein, David J., Lisa Wallner Samstag, Marc Cantillon, et al.. (1996). Follow-up assessment of medication-treated dysthymia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 20(3). 427–442. 8 indexed citations

20.

Molchan, Susan, John A. Matochik, Alan J. Zametkin, et al.. (1994). A Double FDG/PET Study of the Effects of Scopolamine in Older Adults. Neuropsychopharmacology. 10(3). 191–198. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact